GlassScriptPhysician profile
Kristoffer Ryan De Lara
NPI 1104109305
$23,806.82
in general payments reported to CMS, 2019-2025
59 companies · $4,121 in 2025
The $4,121 reported for 2025 was more than what 89% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,065 · 2020: $1,755 · 2021: $4,016 · 2022: $3,551 · 2023: $3,320 · 2024: $2,979 · 2025: $4,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,489 · Travel and Lodging: $931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,488.68 |
| Travel and Lodging | $931.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,230.62 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Patient Trial Kit |
| Abbott Laboratories | $2,579.01 | 2019-2025 | Proclaim, Infinity |
| Collegium Pharmaceutical, INC. | $2,394.76 | 2019-2025 | Xtampza, Belbuca |
| Scilex Pharmaceuticals INC. | $1,478.61 | 2019-2025 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,409.85 | 2019-2025 | Relistor |
| Abbvie INC. | $1,003.52 | 2022-2025 | Qulipta, Ubrelvy |
| Vertos Medical, INC. | $850.17 | 2019-2021 | |
| Grt US Holding, INC. | $791.34 | 2020-2022 | |
| Averitas Pharma INC. | $736.29 | 2023-2025 | Qutenza |
| Medtronic, INC. | $696.44 | 2022-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Saluda Medical Americas, INC. | $611.28 | 2023-2025 | Evoke, Evoke Scs |
| Bioventus LLC | $516.94 | 2021-2024 | Gelsyn-3 |
| Nevro Corp. | $501.98 | 2019-2024 | Senza |
| Redhill Biopharma INC. | $458.25 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $452.73 | 2019-2022 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristoffer De Lara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.